Induction Therapy With Cisplatin, 5-Fluorouracil, Leucovorin, and Paclitaxel in Patients With Head and Neck Cancer.

Autor: EDUARDO COELHO DE SA, CARLOS, GOMES CUBERO, DANIEL DE IRACEMA, ASSUNCAO RIBEIRO DA COSTA, RAFAEL EVERTON, DI PARDO, RENATO, SILVA MELO CRUZ, FELIPE JOSE, DE MELO SETTE, CLÁUDIA VAZ, ARAUJO DA SILVA, ELIANA, DEL GIGLIO, AURO
Předmět:
Zdroj: In Vivo; May/Jun2023, Vol. 37 Issue 3, p1339-1345, 7p
Abstrakt: Background/Aim: This study aimed to evaluate the toxicities and response rate of a modified TPF (docetaxel, cisplatin, and 5-fluorouracil) protocol in patients with locally advanced head and neck cancer (ECOG performance status =1). Patients and Methods: Induction treatment consisted of cisplatin 25 mg/m2/day as a 90 min infusion for three consecutive days, leucovorin 20 mg/m2/day as a bolus for four consecutive days, 5-fluorouracil (5-FU) 370 mg/m2/day as a bolus for four consecutive days, and paclitaxel 60 mg/m2 as a 1-h infusion on Days 1, 8, and 15, repeated every 3-4 weeks (twelve cycles to 6 patients). Results: The main toxicities were grade 1 neuropathy, mucositis, and fatigue. There were four episodes of severe toxicities (grade =3). There was one early death, and 2 patients were discontinued due to hematological toxicity. Other side effects included neutropenia, nausea, diarrhea, and vomiting. Conclusion: Induction therapy with cisplatin, 5-fluorouracil, leucovorin, and paclitaxel in head and neck cancer is not feasible because of severe toxicity. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index